In type 2 diabetes, the incretin effect is diminished and in parallel, post-prandial insulin secretion is deteriorating (2, 5)
The same finding has not yet been confirmed in clinical trials, although there is evidence of striatal vascular formation within cerebral capillaries during the progression of PD (Yang et al
The Verdict Based on the available evidence, it appears that Semaglutide, as a GLP-1 receptor agonist used to manage diabetes, does not directly cause sarcopenia or significant muscle loss
(Sikiric says the agreement was to take it all the way to market, though he declined to show the agreement to Undark.) Parnham also found the experimental results underwhelming
[DOI] [PMC free article] [PubMed] [Google Scholar] 157.Alexandrides T, Moses AC, Smith RJ
USD 39.95 Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others Change history 23 November 2023 A Correction to this paper has been published: References Pisetsky, D